Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding ...

The generic companies that will manufacture and supply lenacapavir to the 120 countries are Dr. Reddy’s, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero and Mylan, a subsidiary of Viatris ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.